Tracazolate
 | |
| Clinical data | |
|---|---|
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.050.178 |
| Chemical and physical data | |
| Formula | C16H24N4O2 |
| Molar mass | 304.394g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tracazolate(ICI-136,753) is ananxiolyticdrugwhich is used in scientific research. It is apyrazolopyridinederivative,most closely related topyrazolopyrimidinedrugs such aszaleplon,and is one of a structurally diverse group of drugs known as thenonbenzodiazepineswhich act at the same receptor targets asbenzodiazepinesbut have distinct chemical structures.[1]
Tracazolate has primarilyanxiolyticandanticonvulsanteffects, withsedativeandmuscle relaxanteffects only appearing at higher doses.[2]It has a unique receptor binding profile involving allosteric modulation of severalGABAAreceptor subtypes, being selective for GABAAreceptors containing α1 and β3 subunits, but exhibiting different effects depending on the third type of subunit making up the receptor complex.[3]
See also[edit]
References[edit]
- ^Patel JB, Malick JB, Salama AI, Goldberg ME (October 1985). "Pharmacology of pyrazolopyridines".Pharmacology, Biochemistry, and Behavior.23(4): 675–80.doi:10.1016/0091-3057(85)90436-8.PMID2866547.S2CID31584179.
- ^Patel JB, Malick JB (March 1982). "Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent".European Journal of Pharmacology.78(3): 323–33.doi:10.1016/0014-2999(82)90034-6.PMID6121711.
- ^Thompson SA, Wingrove PB, Connelly L, Whiting PJ, Wafford KA (April 2002). "Tracazolate reveals a novel type of allosteric interaction with recombinant gamma-aminobutyric acid(A) receptors".Molecular Pharmacology.61(4): 861–9.doi:10.1124/mol.61.4.861.PMID11901225.S2CID7039885.